Humacyte HUMA
NASDAQ HUMA
$0.51 -0.02 (-3.47%)
As of: Sep 30, 2026 · 3:06 PM EDT

Humacyte (HUMA) Preferred Stock Liabilities (2020 - 2021)

Updated

Humacyte (HUMA) posted Preferred Stock Liabilities of $78.7 million for Q2 2021, up 0.4% from the prior quarter.

Analysis

Humacyte (HUMA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

At the end of FY2020, Humacyte's Preferred Stock Liabilities came in at $420.99 million.

  • Quarterly Preferred Stock Liabilities has run from a low of $78.41 million in Q1 2021 to a high of $420.99 million in Q4 2020 over five years.
  • According to Business Quant data, Preferred Stock Liabilities for the three prior quarters was $78.41 million (Q1 2021), $420.99 million (Q4 2020) and $94.36 million (Q3 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn -
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn -
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn -
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn -
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Humacyte 147.23 Mn 147.23 Mn -825,000.00 -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 78.70 Mn
Mar 31, 2021 78.41 Mn
Dec 31, 2020 420.99 Mn
Sep 30, 2020 94.36 Mn
API Access

Humacyte Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=HUMA&period=max&api_key=YOUR_API_KEY